ALGS Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -4256.01% compared to Aligos Therapeutics, Inc.'s net margin of --. Aligos Therapeutics, Inc.'s return on equity of -138.89% beat CEL-SCI Corp.'s return on equity of -266.61%.

Aligos Therapeutics, Inc. has a consensus price target of $80.25, signalling upside risk potential of 703.3%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that Aligos Therapeutics, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Aligos Therapeutics, Inc. is more attractive than CEL-SCI Corp..

Aligos Therapeutics, Inc. has a beta of 2.743, which suggesting that the stock is 174.302% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Aligos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aligos Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Aligos Therapeutics, Inc. quarterly revenues are $741K, which are larger than CEL-SCI Corp. quarterly revenues of --. Aligos Therapeutics, Inc.'s net income of -$31.5M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Aligos Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aligos Therapeutics, Inc. is 33.71x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -4256.01% compared to Aligos Therapeutics, Inc.'s net margin of -953.4%. Aligos Therapeutics, Inc.'s return on equity of -138.89% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Aligos Therapeutics, Inc. has a consensus price target of $80.25, signalling upside risk potential of 703.3%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than Aligos Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Aligos Therapeutics, Inc..

Aligos Therapeutics, Inc. has a beta of 2.743, which suggesting that the stock is 174.302% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Aligos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aligos Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Aligos Therapeutics, Inc. quarterly revenues are $741K, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Aligos Therapeutics, Inc.'s net income of -$31.5M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Aligos Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aligos Therapeutics, Inc. is 33.71x versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -4256.01% compared to Aligos Therapeutics, Inc.'s net margin of -255.85%. Aligos Therapeutics, Inc.'s return on equity of -138.89% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Aligos Therapeutics, Inc. has a consensus price target of $80.25, signalling upside risk potential of 703.3%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Aligos Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Aligos Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Aligos Therapeutics, Inc. has a beta of 2.743, which suggesting that the stock is 174.302% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Aligos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Aligos Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Aligos Therapeutics, Inc. quarterly revenues are $741K, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Aligos Therapeutics, Inc.'s net income of -$31.5M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Aligos Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aligos Therapeutics, Inc. is 33.71x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -4256.01% compared to Aligos Therapeutics, Inc.'s net margin of 13.19%. Aligos Therapeutics, Inc.'s return on equity of -138.89% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Aligos Therapeutics, Inc. has a consensus price target of $80.25, signalling upside risk potential of 703.3%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Aligos Therapeutics, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Aligos Therapeutics, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Aligos Therapeutics, Inc. has a beta of 2.743, which suggesting that the stock is 174.302% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Aligos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aligos Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Aligos Therapeutics, Inc. quarterly revenues are $741K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Aligos Therapeutics, Inc.'s net income of -$31.5M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Aligos Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aligos Therapeutics, Inc. is 33.71x versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.